Apotex Health Corp. APTX.TO
As ofNov 13, 2026, 4:00 PM EST
- YTD
- +46.07%
- 1 year
- +46.07%
- Market cap
- 9.03B
- Revenue (ttm)
- 3.20B
- Profit margin
- -0.85%
- EPS (ttm)
- -0.14
- Shares out
- 228.50M
- Forward P/E
- 16.68
- Dividend
- 0.06 (0.16%)
- Ex-dividend date
- Sep 15, 2026
- YTD return
- +46.07%
- 1-year return
- +46.07%
- Volume
- 506.15K
- Avg volume
- 460.28K
- Open
- 38.50
- Previous close
- 38.46
- Day's range
- 38.50 – 40.10
- 52-week range
- 26.05 – 40.18
5D +4.65 (+13.37%)
Key statistics
- Enterprise value
- 11.55B
- PEG ratio
- 0.00
- Price / sales
- 2.82
- Price / book
- 25.73
- Dividend yield
- 0.16%
- Payout ratio
- 0.00%
- Revenue growth
- -25.80%
- Free cash flow
- 0
- Total cash
- 258.76M
- Total debt
- 3.02B
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 33.04
- 200-day average
- 33.69
About Apotex Health Corp.
Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. The company was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Canada
- Website
- apotex.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on APTX.TO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Alon (Ariel Gershon) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Jun 8, 2026 | 48,622 |
| Fishman (Barry) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Jun 8, 2026 | 66,721 |
| Krinsky (Itzhak) | Director of Issuer | Opening Balance-Initial SEDI Report | Jun 8, 2026 | 33,360 |
| Krishnan (Kiran) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Jun 8, 2026 | 72,933 |
| Mcclelland (Brian George) | Senior Officer of Issuer | Opening Balance-Initial SEDI Report | Jun 8, 2026 | 32,414 |
| Oberman (Allan) | Director of Issuer | Exercise of rights | Sep 17, 2026 | 532,062 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Investment Trust-Fidelity Series Canada Fund | 0.91% | 2,089,792 | 82.42M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Blue Chip Growth Fund | 0.77% | 1,772,100 | 69.89M | Sep 29, 2026 |
| Fidelity Investment Trust-Fidelity Diversified International Fund | 0.42% | 960,600 | 37.89M | Sep 29, 2026 |
| Fidelity Investment TRT-Fidelity SAI Intl SMA Completion Fd. | 0.38% | 865,900 | 34.15M | Sep 29, 2026 |
| Fidelity Securities Fund-Fidelity Blue Chip Growth K6 Fund | 0.16% | 374,300 | 14.76M | Sep 29, 2026 |
| Fidelity Investment Trust-Fidelity Diversified International K6 Fund | 0.15% | 334,010 | 13.17M | Sep 29, 2026 |
